The Dedham Group’s Post

View organization page for The Dedham Group, graphic

17,419 followers

Few drugs have gripped the American public, like GLP-1 weight-loss medications. The strong sales of GLP-1 drugs raise questions about how insulin pricing crackdowns will affect pipeline strategies and how biopharma manufacturers will address supply issues to support diabetes patients. In a recent BioSpace BioSpace article, The Dedham Group’s Manuel Jurado provides commentary on the connection between the GLP-1 and the insulin market. Check out the full article: https://ow.ly/tg7E50RRF6Z #GLP1 #Insulin #Biopharma #PharmaceuticalCompanies

As Sales of Weight Loss Drugs Skyrocket, the Insulin Market Falters | BioSpace

As Sales of Weight Loss Drugs Skyrocket, the Insulin Market Falters | BioSpace

biospace.com

To view or add a comment, sign in

Explore topics